Comparison of the effect of multidrug and single-drug adjuvant chemotherapy on the 5-year survival outcome of high-risk stage II colon cancer

Background: To explore the effect of multidrug and single-drug adjuvant chemotherapy on the 5-year survival outcome of high-risk stage II colon cancer. Methods: Retrospective analysis was conducted on the clinical data of 103 high-risk stage II colon cancer patients admitted to our hospital from June 2016 to December 2017. The data was recorded using different drug adjuvant chemotherapy methods, and the subjects were divided into a multidrug group (n = 52) and a single-drug group (n = 51). The general data of the two groups, including gender, age, tumor location, clinical T stage, and metastatic site, were collected. The propensity score matching method was used to balance the baseline data between the two groups, and the confounding factors were balanced in the two groups. After matching, 29 cases were selected from each group. Follow-up for 5 years, t-test, Chi-square test, and analysis of variance were used to compare the 5-year survival outcome, tumor marker level, quality of life, adjuvant chemotherapy effect, and adverse reaction occurrence of the two groups after matching. Results: The 5-year survival rate of the single-drug group was significantly lower than that of the multidrug group (51.72 versus 79.31), and the difference was statistically significant (P < 0.05). There was no difference in the levels of cyclooxygenase-2 (COX-2), B-lymphocyte tumor-2 gene (Bcl-2), carbohydrate antigen 125 (CA125), and quality of life score before chemotherapy between the two groups (P > 0.05). After chemotherapy, the levels of tumor markers in both groups decreased, and the level of tumor markers in the multidrug group was significantly lower than that of the single-drug group (P < 0.05). The quality of life score in the multidrug group was higher than that in the single-drug group after chemotherapy, and the difference was statistically significant (P < 0.05). After adjuvant chemotherapy, there was no significant difference in the overall response rate between the multidrug group and the single-drug group (37.93 versus 51.72), but the disease control rate in the multidrug chemotherapy group was higher than that in the single-drug chemotherapy group (86.21 versus 62.07). The incidence of adverse reactions in the multidrug group was not significantly different from that in the single-drug group (17.24 versus 24.14). Conclusion: Compared with single-drug adjuvant chemotherapy, patients treated with multidrug adjuvant chemotherapy have better 5-year survival outcom